Q2 2024 Ultimovacs ASA Earnings Call Transcript
Good afternoon, everybody, and welcome to Ultimovacs second-quarter 2024 business update and financial results. As usual, I have with me our Chief Medical Officer, Jens Bjørheim; and our Chief Financial Officer, Hans Vassgård Eid. We will go through the main news from this quarter. (Event Instructions)
If we can move to the next slide, I have to show you the disclaimer. And if we move to the next slide, I will give a brief introduction. Jens will cover the clinical update on UV1. I will have a slide on our novel drug conjugation platform. Hans will cover the financial update, and then I will cover the news flow and end the meeting before Q&A.
Okay. So let's proceed and move to the next slide. Again, this quarter was mainly impacted by the results of INITIUM, FOCUS. Of course, despite these disappointing results and we are sorry for patients. We are still committed as a company and as a team to bring in UV1 across the next important data point, that is the DOVACC readout.
These top line results, as you know, the FOCUS
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |